binding,il-17a

GSK2981278 (ROR gama modulator 1) is a highly potent and selective inverse agonist of retinoic acid receptor-related orphan receptor gamma (ROR gamma).

Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A with a Kd value of <3 pM. It blocks the binding of IL-17A to IL-17RA but not to other IL-17 family members. Ixekizumab is used for the treatment of moderate to severe plaque psoriasis, psoriasis, arthritis, and psoriasis.

MRL-871 is a selective RORγt allosteric inhibitor, reducing IL-17a mRNA production in EL4 cells, interacting with PPARgamma in partial agonistic binding modes.

STK630921 is a blocker of IL-17A binding to the IL-17A receptor (IL-17RA).

Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a human IgGκ monoclonal antibody that specifically targets and inhibits IL-17A's receptor interaction, making it useful for researching autoimmune conditions such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis [1].

Gumokimab (AK 111) is a humanized monoclonal antibody designed to specifically target interleukin-17A (IL-17A). it functions by competitively inhibiting the binding of IL-17A to its cognate receptor, thereby blocking downstream pro-inflammatory signaling, Gumokimab is a candidate for therapeutic research in psoriasis and ankylosing spondylitis.